Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 113-121

  Neufeld, Edward B ^a   Zadrozny, Leah M ^a   Phillips, Darci ^a   Aponte, Angel ^a   Yu, Zu Xi ^a   Balaban, Robert S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Aortic valve; Biglycan; Collagen; Decorin; Elastin; LDL retention; Renal ostia; Two photon microscopy

Indexed keywords

AORTIC VALVE; BIGLYCAN; COLLAGEN; DECORIN; ELASTIN; LDL RETENTION; RENAL OSTIA; TWO PHOTON MICROSCOPY;

ANIMALS; AORTIC VALVE; ATHEROSCLEROSIS; BIGLYCAN; CALCINOSIS; CARDIOMYOPATHIES; DECORIN; HUMANS; LIPOPROTEINS, LDL; PROTEOMICS; STATIC ELECTRICITY; SWINE; TUNICA INTIMA;

EID: 84893937819     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.038     Document Type: Article

References (45)

1. Rajamannan N.M., Evans F.J., Aikawa E., et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation 2011, 124:1783-1791.
2. Grande-Allen K.J., Osman N., Ballinger M.L., Dadlani H., Marasco S., Little P.J. Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease. Cardiovasc Res 2007, 76:19-28.
3. O'Brien K.D. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 2006, 26:1721-1728.
4. Rajamannan N.M. Calcific aortic stenosis: a disease ready for prime time. Circulation 2006, 114:2007-2009.
5. Agmon Y., Khandheria B.K., Meissner I., et al. Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study. JAm Coll Cardiol 2001, 38:827-834.
6. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
7. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
8. Nakashima Y., Fujii H., Sumiyoshi S., Wight T.N., Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 2007, 27:1159-1165.
9. O'Brien K.D., Reichenbach D.D., Marcovina S.M., Kuusisto J., Alpers C.E., Otto C.M. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996, 16:523-532.
10. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. JAm Coll Cardiol 1997, 29:630-634.
11. Weiss R.M., Ohashi M., Miller J.D., Young S.G., Heistad D.D. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006, 114:2065-2069.
12. Miller J.D., Weiss R.M., Serrano K.M., et al. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009, 119:2693-2701.
13. Camejo G. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis. Adv Lipid Res 1982, 19:1-53.
14. Jackson R.L., Busch S.J., Cardin A.D. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991, 71:481-539.
15. O'Brien K.D., Olin K.L., Alpers C.E., et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998, 98:519-527.
16. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998, 139:205-222.
17. Mourao P.A., Pillai S., Di F.N. The binding of chondroitin 6-sulfate to plasma low density lipoprotein. Biochim Biophys Acta 1981, 674:178-187.
18. Bancells C., Benitez S., Jauhiainen M., et al. High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level. JLipid Res 2009, 50:446-455.
19. Talusan P., Bedri S., Yang S., et al. Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics 2005, 4:1350-1357.
20. Stephens E.H., Saltarrelli J.G., Baggett L.S., et al. Differential proteoglycan and hyaluronan distribution in calcified aortic valves. Cardiovasc Pathol 2010, 20:334-342.
21. Huang F., Thompson J.C., Wilson P.G., Aung H.H., Rutledge J.C., Tannock L.R. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. JLipid Res 2008, 49:521-530.
22. Kwon G.P., Schroeder J.L., Amar M.J., Remaley A.T., Balaban R.S. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation 2008, 117:2919-2927.
23. Neufeld E.B., Yu Z.X., Springer D., Yu Q., Balaban R.S. The renal artery ostium flow diverter: structure and potential role in atherosclerosis. Atherosclerosis 2010, 211:153-158.
24. Casscells W., Kimura H., Sanchez J.A., Yu Z.X., Ferrans V.J. Immunohistochemical study of fibronectin in experimental myocardial infarction. Am J Pathol 1990, 137:801-810.
25. Li D., Clark C.C., Myers J.C. Basement membrane zone type XV collagen is a disulfide-bonded chondroitin sulfate proteoglycan in human tissues and cultured cells. JBiol Chem 2000, 275:22339-22347.
26. Halfter W., Dong S., Schurer B., Cole G.J. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. JBiol Chem 1998, 273:25404-25412.
27. Burg M.A., Tillet E., Timpl R., Stallcup W.B. Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. JBiol Chem 1996, 271:26110-26116.
28. Douglas T., Heinemann S., Bierbaum S., Scharnweber D., Worch H. Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan. Biomacromolecules 2006, 7:2388-2393.
29. Kadler K.E., Hill A., Canty-Laird E.G. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol 2008, 20:495-501.
30. Lethias C., Carisey A., Comte J., Cluzel C., Exposito J.Y. Amodel of tenascin-X integration within the collagenous network. FEBS Lett 2006, 580:6281-6285.
31. Barkalow F.J., Schwarzbauer J.E. Interactions between fibronectin and chondroitin sulfate are modulated by molecular context. JBiol Chem 1994, 269:3957-3962.
32. Elefteriou F., Exposito J.Y., Garrone R., Lethias C. Binding of tenascin-X to decorin. FEBS Lett 2001, 495:44-47.
33. Pentikainen M.O., Oorni K., Lassila R., Kovanen P.T. The proteoglycan decorin links low density lipoproteins with collagen type I. JBiol Chem 1997, 272:7633-7638.
34. Camejo G., Olofsson S.O., Lopez F., Carlsson P., Bondjers G. Identification of Apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis 1988, 8:368-377.
35. Gordon M.K., Hahn R.A. Collagens. Cell Tissue Res 2010, 339:247-257.
36. Wiberg C., Klatt A.R., Wagener R., et al. Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan. JBiol Chem 2003, 278:37698-37704.
37. Brown D.C., Vogel K.G. Characteristics of the invitro interaction of a small proteoglycan (PG II) of bovine tendon with type I collagen. Matrix 1989, 9:468-478.
38. Vogel K.G., Paulsson M., Heinegard D. Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem J 1984, 223:587-597.
39. Nareyeck G., Seidler D.G., Troyer D., Rauterberg J., Kresse H., Schonherr E. Differential interactions of decorin and decorin mutants with type I and type VI collagens. Eur J Biochem 2004, 271:3389-3398.
40. Moulton K.S., Olsen B.R., Sonn S., Fukai N., Zurakowski D., Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004, 110:1330-1336.
41. Minomo A., Ishima Y., Kragh-Hansen U., et al. Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXalpha revealed by phage display. FEBS J 2011, 278:4100-4111.
42. Moosavi-Movahedi Z., Bahrami H., Zahedi M., et al. Atheoretical elucidation of bilirubin interaction with HSA's lysines: first electrostatic binding site in IIA subdomain. Biophys Chem 2007, 125:375-387.
43. Ghuman J., Zunszain P.A., Petitpas I., Bhattacharya A.A., Otagiri M., Curry S. Structural basis of the drug-binding specificity of human serum albumin. JMol Biol 2005, 353:38-52.
44. Skalen K., Gustafsson M., Rydberg E.K., et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750-754.
45. Soto Y., Acosta E., Delgado L., et al. Antiatherosclerotic effect of an antibody that binds to extracellular matrix glycosaminoglycans. Arterioscler Thromb Vasc Biol 2012, 32:595-604.